{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"CB defined as percentage of participants with sCR, CR, VGPR, PR or Minor/minimal response (MR) assessed by IMWG criteria. sCR: CR as defined plus normal FLC ratio \\& absence of clonal cells. CR: negative immunofixation on serum \\& urine; disappearance of any soft tissue plasmacytomas; \\<5% plasma cells in bone marrow; normal FLC ratio: 0.26-1.65. VGPR: serum \\& urine M-protein detectable by immunofixation; \\>=90% reduction in serum M-protein plus urine M-protein level \\<100 mg/24h; \\>90% decrease in difference between involved \\& uninvolved FLC levels required. PR: \\>=50% reduction of serum M-protein \\& reduction in 24h urinary M protein by \\>=90%/\\<200 mg/24 h; if serum \\& urine M-protein unmeasurable:\\>=50% decrease in difference between involved \\& uninvolved FLC; if serum \\& urine M-protein not measurable:\\>=50% reduction in plasma cells required. MR: \\>=25% but \\<=49% reduction of serum M protein and reduction in 24h urine M protein by 50-89%; 25-49% reduction in size of soft tissue plasmacytomas.","groups":[{"description":"Participants received Isatuximab 20 mg/kg IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 248 weeks).","id":"OG000","title":"Phase 2: Isatuximab 20 mg/kg"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on all treated population. Data for this outcome measure was not planned to be collected and analyzed for Phase 1.","reportingStatus":"POSTED","timeFrame":"From date of first study treatment administration until first documented response, or death due to any cause, whichever comes first (maximum duration of exposure: up to 248 weeks)","title":"Phase 2: Percentage of Participants With Clinical Benefit (CB)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}